- Home
- OMCL vs IMTX Comparison
OMCL vs IMTX Comparison
Compare OMCL & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | IMTX |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMCL | IMTX |
|---|---|---|
| Price | $36.32 | $10.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $53.67 | $19.00 |
| AVG Volume (30 Days) | ★ 394.2K | 361.6K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $787,309,000.00 | N/A |
| Revenue This Year | $6.77 | N/A |
| Revenue Next Year | $5.22 | $25.91 |
| P/E Ratio | $875.00 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $22.66 | $3.94 |
| 52 Week High | $51.84 | $12.41 |
Technical Indicators
Market Signals| Indicator | OMCL | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 62.85 |
| Support Level | $35.38 | $9.66 |
| Resistance Level | $37.51 | $11.30 |
| Average True Range (ATR) | 1.43 | 0.49 |
| MACD | 0.50 | 0.13 |
| Stochastic Oscillator | 82.18 | 88.71 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.